Lenabasum clinical trials
Also written JBT-101.
How each study uses lenabasum is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2017 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Corbus Pharmaceuticals Inc. (6) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Studies
Open first, then newest update. How each study uses lenabasum is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- JBT-101 in Systemic Lupus Erythematosus (SLE)CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03093402Written as JBT-101
- Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisTerminatedPhase 2Corbus Pharmaceuticals Inc.NCT02466243Written as JBT-101
- Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCompletedPhase 2Corbus Pharmaceuticals Inc.NCT03451045Written as Lenabasum 20 mg
- Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisCompletedPhase 3Corbus Pharmaceuticals Inc.NCT03813160Written as Lenabasum 20 mg
- Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisTerminatedPhase 2Corbus Pharmaceuticals Inc.NCT02465437Written as JBT-101
- Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisTerminatedPhase 3Corbus Pharmaceuticals Inc.NCT03398837Written as Lenabasum 5 mg
- Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisCompletedPhase 2Corbus Pharmaceuticals Inc.NCT02465450Written as JBT-101 (lenabasum)
Codes
What other systems call lenabasum · ClinicalTrials.gg INT004508
- MeSH (NLM) C471849lenabasumConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) OGN7X90BT8LENABASUMConfirmed FDA, NLM
- NCI Thesaurus C174799LenabasumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C471849 | lenabasum | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OGN7X90BT8 | LENABASUM | Confirmed FDA, NLM |
| NCI Thesaurus | C174799 | Lenabasum | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.